Clinical Trial Update: Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating nivolumab in patients with metastatic renal cell carcinoma who progressed during or after anti-angiogenic therapy has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: UNICANCER | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: COMPLETED